Page results
-
A new CAR T-cell therapy developed by scientists at UCL has fewer ‘toxic’ side-effects and is more durable, targeting and killing cancer cells for longer, concludes a Phase 1 clinical trial of patients at UCLH.
-
The National Paediatric Diabetes Audit (NPDA) is asking all children and young people (8-19 years) and parents/carers (of children under 8 years old) who have received diabetes care in the past 6 months, to fill in the survey.
-
UCLH NHS Foundation Trust has once again formed a partnership with the Business Design Centre in Islington to reopen a large-scale COVID-19 vaccination centre on site from Saturday 18 December.
-
University College London Hospitals (UCLH) is now administering new COVID-19 treatments for patients at highest risk in the community.
-
Having proton beam therapy: information for children aged 5-8 patient information page.
-
Having proton beam therapy: information for children aged 9-12 patient information
-
Having proton beam therapy: information for teenagers aged 13-17 patient information.
-
Our vaccination centre at the Business Design Centre, Islington, closed on Monday 10 January.
-
This Mobile Health Clinic has been extensively refurbished and fitted with a new digital portable x-ray camera and modern technologies to speed patient diagnoses and treatment of infectious diseases that will be powered on green energy.
-
The haematology and critical care services in our flagship University College Hospital Grafton Way Building are now open.
File results
-
FOI/2022/0477 - The Integrated Care Board (ICB) that commissions services from Trust
-
FOI/2022/0478 - Hospital-initiated cancellation of appointments
-
FOI/2022/0481 - Electronic Patient Record system
-
FOI/2022/0482 - Non-emergency patient transport service (NEPTS)
-
FOI/2022/0485 - ACR laboratory device
-
FOI/2022/0486 - Dermatology dept staff details
-
FOI/2022/0487 - ICT spend on telecommunication, mobile handsets/ smartphones
-
FOI/2022/0488 - Robotic process automation
-
FOI/2022/0489 - Prescribed PrEP medication
-
FOI/2022/0494 - Treatment of Haemophilia A